Skip to main content
Fig. 3 | Journal of Biomedical Science

Fig. 3

From: The ‘speck’-tacular oversight of the NLRP3-pyroptosis pathway on gastrointestinal inflammatory diseases and tumorigenesis

Fig. 3

Novel therapeutical approaches targeting NLRP3 inflammasome activation. Several compounds targeting NLRP3-pyroptosis pathway at different stage of activation, able to prevent the activation of Th1 cells and gut inflammation, are currently under clinical trials. MCC950, OLT1177, IFM-2427 and NT-0167 interfere with NLRP3 oligomerization; Oridonin and INF39 hinder the binding between NLRP3 and NEK7; Disulfiram is a potent inhibitor of GSDMD-mediates plasma membrane pores and pyroptotic cell death

Back to article page

Journal of Biomedical Science

ISSN: 1423-0127